<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7496561\results\search\testTrace\results.xml">
  <result pre="In spite of various governments implementing aggressive global lock-down and" exact="quarantine" post="protocols, the number of cases continues to follow an"/>
  <result pre="therapeutic options. covid-19 sars-cov-2 2019 n-cov coronavirus antiviral drug remdesivir" exact="treatment" post="The content published in Cureus is the result of"/>
  <result pre="[5]. Another approach involves looking through the existing compounds and" exact="testing" post="their efficacy for antiviral properties including information about transcription"/>
  <result pre="A combination of these approaches can help us to evolve" exact="treatment" post="options that we can broadly classify into being virus-based"/>
  <result pre="which include bats, cats, camels, cattle, and cases of COVID" exact="infection" post="have also been detected in feline families in the"/>
  <result pre="the potential for repurposing existing antiviral agents to treat SARS-CoV-2" exact="infection" post="with their site of action as shown in Figure"/>
  <result pre="study for HIV prevention, its potency and efficacy for the" exact="treatment" post="or prevention of SARS-CoV-2 should be researched further [4]."/>
  <result pre="is one of the most important drugs named in the" exact="treatment" post="of COVID-19 and is being extensively researched. In 2017,"/>
  <result pre="extensively researched. In 2017, Gilead Sciences developed RDV for the" exact="treatment" post="of Ebola virus infection. It is a broad-spectrum drug"/>
  <result pre="of RDV was more effective than a placebo in the" exact="treatment" post="of hospitalized patients with COVID-19. The benefit was seen"/>
  <result pre="issued an Emergency Use Authorization (EUA) for RDV for the" exact="treatment" post="of adults and children hospitalized with severe suspected or"/>
  <result pre="intravenous (IV) agent is clinically appropriate [16].Â Patient selection and" exact="treatment" post="initiation: the selection of patients and treatment initiation are"/>
  <result pre="Patient selection and treatment initiation: the selection of patients and" exact="treatment" post="initiation are as follows: - Empiric treatment can be"/>
  <result pre="of patients and treatment initiation are as follows: - Empiric" exact="treatment" post="can be initiated in suspected COVID-19 patients whose laboratory"/>
  <result pre="before dosing and daily while receiving RDV. - Hepatic laboratory" exact="testing" post="should be performed in all patients before starting RDV."/>
  <result pre="trials are ongoing on the use of RDV for the" exact="treatment" post="of COVID-19. Therapeutic Apheresis (Plasma Exchange or Cytapheresis) Current"/>
  <result pre="possibility of the usage of convalescent plasma for prevention and/or" exact="treatment" post="gathered interest during the West African Ebola outbreak. Various"/>
  <result pre="of plasma exchange provides a potentially promising option until other" exact="treatment" post="options and vaccines are being explored [20]. Plasma exchange"/>
  <result pre="FDA has laid down certain guidelines regarding patient eligibility for" exact="treatment" post="with plasma exchange:Â 1. Laboratory-confirmed COVID-19 2. Severe or"/>
  <result pre="is to prevent or treat malaria and also in the" exact="treatment" post="of several infections like HIV, Q fever, WhippleÂ disease,"/>
  <result pre="and hydroxychloroquine are 4-aminoquinolines that are under trial for the" exact="treatment" post="ofÂ COVID-19. Currently, many clinical trials are ongoing worldwide"/>
  <result pre="with various guidelines, the effective dose of chloroquine for the" exact="treatment" post="of COVID-19 infection has been found to be 500"/>
  <result pre="the effective dose of chloroquine for the treatment of COVID-19" exact="infection" post="has been found to be 500 mg twice daily"/>
  <result pre="concerns regarding the safety of hydroxychloroquine in high doses for" exact="treatment" post="in critically ill patients with COVID-19 [30]. Hydroxychloroquine can"/>
  <result pre="(IL-6R). It has been approved by the FDA for the" exact="treatment" post="of severe chimeric antigen receptor (CAR) T cell-induced CRS,Â"/>
  <result pre="Its use in patients with tuberculosis (TB) or any active" exact="infection" post="is contraindicated. Elevated IL-6 levels have been seen as"/>
  <result pre="cell growth. Baricitinib, a JAK inhibitor, is used in the" exact="treatment" post="of some types of malignancies and autoimmune diseases such"/>
  <result pre="hypothesizedÂ using artificial intelligence (AI)-algorithmsÂ to be useful for the" exact="treatment" post="of COVID-19 infection via proposed anti-cytokine effects and as"/>
  <result pre="intelligence (AI)-algorithmsÂ to be useful for the treatment of COVID-19" exact="infection" post="via proposed anti-cytokine effects and as an inhibitor of"/>
  <result pre="as high as 29-42%. Co-infection is a significantÂ threat during" exact="treatment" post="with baricitinib. There is an increased risk of reactivation"/>
  <result pre="ribavirin nucleoside analogs by coronavirus proofreading mechanism. Subsequent in vivo" exact="testing" post="showed that monotherapy with ribavirin showed restricted activity against"/>
  <result pre="ACE2 receptors are at a higher risk for severe COVID-19" exact="infection" post="[46]. Therefore, the balance of potential benefits and harms"/>
  <result pre="ACEI or angiotensin receptor blockersÂ (ARB)Â therapy during an acute" exact="infection" post="depends on the reason for prescribing. Although these drugs"/>
  <result pre="infection, they are not being viewed as a potential COVID-19" exact="treatment" post="option. Currently, there are some clinical trials focussing on"/>
  <result pre="options There are many emerging options being tried for the" exact="treatment" post="of COVID-19. We have listed a few important ones.Â"/>
  <result pre="the virus with the host cells. A study with Arbidol" exact="treatment" post="showed it to be possibly superior to LPV/ritonavir in"/>
  <result pre="[47]. Favipiravir Favipiravir is an antiviral drug approved for the" exact="treatment" post="of influenza in Japan due to its activity against"/>
  <result pre="Phase 3 Estudios ClÃ­nicos Latino AmÃ©rica Drug: colchicine plus symptomatic" exact="treatment" post="(paracetamol); drug: symptomatic treatment (paracetamol or best symptomatic treatment"/>
  <result pre="Latino AmÃ©rica Drug: colchicine plus symptomatic treatment (paracetamol); drug: symptomatic" exact="treatment" post="(paracetamol or best symptomatic treatment based on doctor recommendations)"/>
  <result pre="symptomatic treatment (paracetamol); drug: symptomatic treatment (paracetamol or best symptomatic" exact="treatment" post="based on doctor recommendations) NCT04416334 1028 May 2020â€&quot;December 2020"/>
  <result pre="drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate; drug: basic" exact="treatment" post="NCT04286503 520 February 2020â€&quot;February 2021 Phase 4 Beijing YouAn"/>
  <result pre="2021 Phase 4 Beijing YouAn Hospital Drug: Arbidol; other: basic" exact="treatment" post="NCT04260594 380 February 2020â€&quot;December 2020 Phase 4 Jieming QU"/>
  <result pre="the virus will be a particularly challenging task. Social distancing," exact="contact tracing," post="and self-isolation are important strategies to avoid the spread"/>
  <result pre="self-isolation are important strategies to avoid the spread of COVID-19" exact="infection" post="as mentioned by the Centers for Disease Control and"/>
  <result pre="the 2019 novel coronavirus (2019-nCoV)Nat Rev Drug DiscovLiGDe ClercqE14915019202032127666 5Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci TrendsLuH697114202031996494 6Features, Evaluation"/>
  <result pre="coronavirus structure by BioRender.com920202020https://app.biorender.com/biorender-templates 12Review of emerging pharmacotherapy for the" exact="treatment" post="of coronavirus disease 2019PharmacotherapyBarlowALandolfKMBarlowBYeungSYHeavnerJClaassenCWHeavnerM41643740202032259313 13Learning from the past: possible"/>
  <result pre="disease 2019PharmacotherapyBarlowALandolfKMBarlowBYeungSYHeavnerJClaassenCWHeavnerM41643740202032259313 13Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019â€�nCoVChemBioChemMorseJSLalondeTXuSLiuWR73073821202032022370"/>
  <result pre="US HCPs920202020https://www.remdesivir.com/us/ 17Gilead Sciences statement on the initiation of clinical" exact="testing" post="of an inhaled solution of remdesivir for potential outpatient"/>
  <result pre="testing of an inhaled solution of remdesivir for potential outpatient" exact="treatment" post="of COVID-19920202020https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-initiation-of-clinical-testing-of-an-inhaled-solution-of-remdesivir-for-potential-outpatient-treatment-of-covid19 18Guidelines on the use of therapeutic apheresis"/>
  <result pre="al.17135434201931180581 19 Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J Clin InvestBlochEMShohamSCasadevallAet al.27572765130202032254064 20Treatment for emerging viruses:"/>
  <result pre="authorization for chloroquine and hydroxychloroquine82020CommissionerO2020https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and 28Chloroquine and hydroxychloroquine in the" exact="treatment" post="of COVID-19 with or without diabetes: a systematic search"/>
  <result pre="Actemra (tocilizumab) injection package insertCA82020GenentechGenentech2018https://www.gene.com/download/pdf/actemra_prescribing.pdf 36FDA approval summary: tocilizumab for" exact="treatment" post="of chimeric antigen receptor T cell-induced severe or life-threatening"/>
  <result pre="AutoimmunLiuBLiMZhouZGuanXXiangY102452111202032291137 38Coronavirus disease 2019 (COVID-19): a clinical updateFront MedZhouMZhangXQuJ12613514202032240462 39Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci"/>
  <result pre="of current evidenceEcancermedicalscienceRussellBMossCGeorgeGSantaolallaACopeAPapaSVan HemelrijckM102214202032256705 41Mechanism of baricitinib supports artificial intelligence-predicted" exact="testing" post="in COVID-19 patientsEMBO Mol MedStebbingJKrishnanVde BonoSet al.0122020 42Janus kinase"/>
  <result pre="J Antimicrob AgentsPraveenDPuvvadaRCMVA10596755202032259575 43The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
  <result pre="inhibitors, repurposing against COVID-19Life SciElfikyAA117477248202032119961 46Outcomes in patients with COVID-19" exact="infection" post="taking ACEI/ARBCurr Cardiol RepRico-MesaJSWhiteAAndersonAS3122202032291526 47Home page: ClinicalTrials.gov920202020https://clinicaltrials.gov/ 48Mesenchymal stem"/>
 </snippets>
</snippetsTree>
